Type B hepatitis after needle-stick exposure

prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study

L. B. Seeff, E. C. Wright, H. J. Zimmerman, H. J. Alter, A. A. Dietz, B. F. Felsher, J. D. Finkelstein, P. Garcia-Pont, J. L. Gerin, H. B. Greenlee, J. Hamilton, P. V. Holland, P. M. Kaplan, T. Kiernan, R. S. Koff, C. M. Leevy, V. J. McAuliffe, N. Nath, R. H. Purcell, Eugene R Schiff & 5 others C. C. Schwartz, C. H. Tamburro, Z. Vlahcevic, R. Zemel, D. S. Zimmon

Research output: Contribution to journalArticle

243 Citations (Scopus)

Abstract

Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to B surface antigen (HBsAg)-positive donors. Clinical hepatitis developed in 1.4% of HBIG in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P < 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBe). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.

Original languageEnglish
Pages (from-to)285-293
Number of pages9
JournalAnnals of Internal Medicine
Volume88
Issue number3
StatePublished - Dec 11 1978
Externally publishedYes

Fingerprint

Needlestick Injuries
United States Department of Veterans Affairs
Hepatitis B
Immunoglobulins
Serum Globulins
Immune Sera
Hepatitis B e Antigens
DNA-Directed DNA Polymerase
Hepatitis B Surface Antigens
Surface Antigens
Hepatitis
Anti-Idiotypic Antibodies
Placebos

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Seeff, L. B., Wright, E. C., Zimmerman, H. J., Alter, H. J., Dietz, A. A., Felsher, B. F., ... Zimmon, D. S. (1978). Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study. Annals of Internal Medicine, 88(3), 285-293.

Type B hepatitis after needle-stick exposure : prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study. / Seeff, L. B.; Wright, E. C.; Zimmerman, H. J.; Alter, H. J.; Dietz, A. A.; Felsher, B. F.; Finkelstein, J. D.; Garcia-Pont, P.; Gerin, J. L.; Greenlee, H. B.; Hamilton, J.; Holland, P. V.; Kaplan, P. M.; Kiernan, T.; Koff, R. S.; Leevy, C. M.; McAuliffe, V. J.; Nath, N.; Purcell, R. H.; Schiff, Eugene R; Schwartz, C. C.; Tamburro, C. H.; Vlahcevic, Z.; Zemel, R.; Zimmon, D. S.

In: Annals of Internal Medicine, Vol. 88, No. 3, 11.12.1978, p. 285-293.

Research output: Contribution to journalArticle

Seeff, LB, Wright, EC, Zimmerman, HJ, Alter, HJ, Dietz, AA, Felsher, BF, Finkelstein, JD, Garcia-Pont, P, Gerin, JL, Greenlee, HB, Hamilton, J, Holland, PV, Kaplan, PM, Kiernan, T, Koff, RS, Leevy, CM, McAuliffe, VJ, Nath, N, Purcell, RH, Schiff, ER, Schwartz, CC, Tamburro, CH, Vlahcevic, Z, Zemel, R & Zimmon, DS 1978, 'Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study', Annals of Internal Medicine, vol. 88, no. 3, pp. 285-293.
Seeff, L. B. ; Wright, E. C. ; Zimmerman, H. J. ; Alter, H. J. ; Dietz, A. A. ; Felsher, B. F. ; Finkelstein, J. D. ; Garcia-Pont, P. ; Gerin, J. L. ; Greenlee, H. B. ; Hamilton, J. ; Holland, P. V. ; Kaplan, P. M. ; Kiernan, T. ; Koff, R. S. ; Leevy, C. M. ; McAuliffe, V. J. ; Nath, N. ; Purcell, R. H. ; Schiff, Eugene R ; Schwartz, C. C. ; Tamburro, C. H. ; Vlahcevic, Z. ; Zemel, R. ; Zimmon, D. S. / Type B hepatitis after needle-stick exposure : prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study. In: Annals of Internal Medicine. 1978 ; Vol. 88, No. 3. pp. 285-293.
@article{0acb92dd3ac745d19b0dd4a880d29235,
title = "Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study",
abstract = "Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to B surface antigen (HBsAg)-positive donors. Clinical hepatitis developed in 1.4{\%} of HBIG in 5.9{\%} of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6{\%} and 20.7{\%} of them respectively (P < 0.001). Mild and transient side-effects were noted in 3.0{\%} of ISG and in 3.2{\%} of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBe). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.",
author = "Seeff, {L. B.} and Wright, {E. C.} and Zimmerman, {H. J.} and Alter, {H. J.} and Dietz, {A. A.} and Felsher, {B. F.} and Finkelstein, {J. D.} and P. Garcia-Pont and Gerin, {J. L.} and Greenlee, {H. B.} and J. Hamilton and Holland, {P. V.} and Kaplan, {P. M.} and T. Kiernan and Koff, {R. S.} and Leevy, {C. M.} and McAuliffe, {V. J.} and N. Nath and Purcell, {R. H.} and Schiff, {Eugene R} and Schwartz, {C. C.} and Tamburro, {C. H.} and Z. Vlahcevic and R. Zemel and Zimmon, {D. S.}",
year = "1978",
month = "12",
day = "11",
language = "English",
volume = "88",
pages = "285--293",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Type B hepatitis after needle-stick exposure

T2 - prevention with hepatitis B immune globulin: final report of Veterans Administration cooperative study

AU - Seeff, L. B.

AU - Wright, E. C.

AU - Zimmerman, H. J.

AU - Alter, H. J.

AU - Dietz, A. A.

AU - Felsher, B. F.

AU - Finkelstein, J. D.

AU - Garcia-Pont, P.

AU - Gerin, J. L.

AU - Greenlee, H. B.

AU - Hamilton, J.

AU - Holland, P. V.

AU - Kaplan, P. M.

AU - Kiernan, T.

AU - Koff, R. S.

AU - Leevy, C. M.

AU - McAuliffe, V. J.

AU - Nath, N.

AU - Purcell, R. H.

AU - Schiff, Eugene R

AU - Schwartz, C. C.

AU - Tamburro, C. H.

AU - Vlahcevic, Z.

AU - Zemel, R.

AU - Zimmon, D. S.

PY - 1978/12/11

Y1 - 1978/12/11

N2 - Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to B surface antigen (HBsAg)-positive donors. Clinical hepatitis developed in 1.4% of HBIG in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P < 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBe). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.

AB - Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to B surface antigen (HBsAg)-positive donors. Clinical hepatitis developed in 1.4% of HBIG in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P < 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBe). Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups. The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.

UR - http://www.scopus.com/inward/record.url?scp=0017878739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017878739&partnerID=8YFLogxK

M3 - Article

VL - 88

SP - 285

EP - 293

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -